source
- Marengo's bispecific antibody invikafusp alfa shows tumor shrinkage in 8 cancer types in Phase 2Marengo Therapeutics presented Phase 2 data for its bispecific antibody invikafusp alfa at the European Society for Medical Oncology meeting in Madrid. The study, part of the Start-001 first‑in‑hum…
- Alnylam to launch pivotal Huntington’s trial after early study shows strong huntingtin knockdownAlnylam Pharmaceuticals announced plans to move its Huntington’s disease RNAi therapy brezosiran into a pivotal, placebo‑controlled trial slated for 2027, pending regulatory alignment. The decisio…